Chair
Member
Chairman of the board
Financial expert
Audit Committee Position

Barbra Keck  

Barbra Keck has served as a member of our board of directors since the Closing of the Exchange. Since February 2021, Barbra has served as the Chief Financial Officer of Deverra Therapeutics, Inc., a developer of cell therapies. From January 2009 until May 2020, she held positions of increasing responsibility at Delcath Systems, Inc., an interventional oncology company, starting as Controller and ultimately becoming a senior vice president in March 2015 and chief financial officer in February 2017. Barbra received an M.B.A. in Accountancy from Baruch College and a Bachelor of Music in Music Education from the University of Dayton.

Chair

Simon King

Simon King, PhD. has served as a member of the board of directors at SmartKem since January 2012 and is a Partner at Octopus Ventures, a London and New York based venture capital fund. At Octopus Ventures, Simon focuses on deeptech investing in early-stage companies. Simon received his M.A. and M.Sc. in Physics from Cambridge University and his Ph.D. in Physical Chemistry from Imperial College London.

Member

Klaas de Boer

Klaas de Boer has served as a member of SmartKem’s board of directors since the Closing of the Exchange. Klaas has been a venture capitalist for more than 20 years, and has served as the Managing Partner of Entrepreneurs Fund Management LLP, a venture capital firm, since January 2008. In that capacity he served on numerous boards, including Lifeline Scientific Inc. and Heliocentris Energy Solutions AG. He currently chairs AIM listed Xeros Technology Group plc, and General Fusion, Inc., and serves on the boards of vasopharm GmbH and D3O Holdings Ltd. Klaas received his M.Sc. degree in Applied Physics from Delft University of Technology and his M.B.A. from INSEAD.

Member

Audit Committee Charter

Download
Compensation Committee Position

Simon King

Simon King, PhD. has served as a member of the board of directors at SmartKem since January 2012 and is a Partner at Octopus Ventures, a London and New York based venture capital fund. At Octopus Ventures, Simon focuses on deeptech investing in early-stage companies. Simon received his M.A. and M.Sc. in Physics from Cambridge University and his Ph.D. in Physical Chemistry from Imperial College London.

Chair

Barbra Keck  

Barbra Keck has served as a member of our board of directors since the Closing of the Exchange. Since February 2021, Barbra has served as the Chief Financial Officer of Deverra Therapeutics, Inc., a developer of cell therapies. From January 2009 until May 2020, she held positions of increasing responsibility at Delcath Systems, Inc., an interventional oncology company, starting as Controller and ultimately becoming a senior vice president in March 2015 and chief financial officer in February 2017. Barbra received an M.B.A. in Accountancy from Baruch College and a Bachelor of Music in Music Education from the University of Dayton.

Member

Compensation Committee Charter

Download
Nominating and Corporate Governance Committee Position

Klaas de Boer

Klaas de Boer has served as a member of SmartKem’s board of directors since the Closing of the Exchange. Klaas has been a venture capitalist for more than 20 years, and has served as the Managing Partner of Entrepreneurs Fund Management LLP, a venture capital firm, since January 2008. In that capacity he served on numerous boards, including Lifeline Scientific Inc. and Heliocentris Energy Solutions AG. He currently chairs AIM listed Xeros Technology Group plc, and General Fusion, Inc., and serves on the boards of vasopharm GmbH and D3O Holdings Ltd. Klaas received his M.Sc. degree in Applied Physics from Delft University of Technology and his M.B.A. from INSEAD.

Chair

Simon King

Simon King, PhD. has served as a member of the board of directors at SmartKem since January 2012 and is a Partner at Octopus Ventures, a London and New York based venture capital fund. At Octopus Ventures, Simon focuses on deeptech investing in early-stage companies. Simon received his M.A. and M.Sc. in Physics from Cambridge University and his Ph.D. in Physical Chemistry from Imperial College London.

Member

Barbra Keck  

Barbra Keck has served as a member of our board of directors since the Closing of the Exchange. Since February 2021, Barbra has served as the Chief Financial Officer of Deverra Therapeutics, Inc., a developer of cell therapies. From January 2009 until May 2020, she held positions of increasing responsibility at Delcath Systems, Inc., an interventional oncology company, starting as Controller and ultimately becoming a senior vice president in March 2015 and chief financial officer in February 2017. Barbra received an M.B.A. in Accountancy from Baruch College and a Bachelor of Music in Music Education from the University of Dayton.

Member

Nominating and Corporate Governance Committee Charter

Download

Barbra Keck

Barbra Keck has served as a member of our board of directors since the Closing of the Exchange. Since February 2021, Barbra has served as the Chief Financial Officer of Deverra Therapeutics, Inc., a developer of cell therapies. From January 2009 until May 2020, she held positions of increasing responsibility at Delcath Systems, Inc., an interventional oncology company, starting as Controller and ultimately becoming a senior vice president in March 2015 and chief financial officer in February 2017. Barbra received an M.B.A. in Accountancy from Baruch College and a Bachelor of Music in Music Education from the University of Dayton.

Simon King

Simon King, PhD. has served as a member of the board of directors at SmartKem since January 2012 and is a Partner at Octopus Ventures, a London and New York based venture capital fund. At Octopus Ventures, Simon focuses on deeptech investing in early-stage companies. Simon received his M.A. and M.Sc. in Physics from Cambridge University and his Ph.D. in Physical Chemistry from Imperial College London.

Klaas de Boer

Klaas de Boer has served as a member of SmartKem’s board of directors since the Closing of the Exchange. Klaas has been a venture capitalist for more than 20 years, and has served as the Managing Partner of Entrepreneurs Fund Management LLP, a venture capital firm, since January 2008. In that capacity he served on numerous boards, including Lifeline Scientific Inc. and Heliocentris Energy Solutions AG. He currently chairs AIM listed Xeros Technology Group plc, and General Fusion, Inc., and serves on the boards of vasopharm GmbH and D3O Holdings Ltd. Klaas received his M.Sc. degree in Applied Physics from Delft University of Technology and his M.B.A. from INSEAD.

Simon King

Simon King, PhD. has served as a member of the board of directors at SmartKem since January 2012 and is a Partner at Octopus Ventures, a London and New York based venture capital fund. At Octopus Ventures, Simon focuses on deeptech investing in early-stage companies. Simon received his M.A. and M.Sc. in Physics from Cambridge University and his Ph.D. in Physical Chemistry from Imperial College London.

Barbra Keck

Barbra Keck has served as a member of our board of directors since the Closing of the Exchange. Since February 2021, Barbra has served as the Chief Financial Officer of Deverra Therapeutics, Inc., a developer of cell therapies. From January 2009 until May 2020, she held positions of increasing responsibility at Delcath Systems, Inc., an interventional oncology company, starting as Controller and ultimately becoming a senior vice president in March 2015 and chief financial officer in February 2017. Barbra received an M.B.A. in Accountancy from Baruch College and a Bachelor of Music in Music Education from the University of Dayton.

Klaas de Boer

Klaas de Boer has served as a member of SmartKem’s board of directors since the Closing of the Exchange. Klaas has been a venture capitalist for more than 20 years, and has served as the Managing Partner of Entrepreneurs Fund Management LLP, a venture capital firm, since January 2008. In that capacity he served on numerous boards, including Lifeline Scientific Inc. and Heliocentris Energy Solutions AG. He currently chairs AIM listed Xeros Technology Group plc, and General Fusion, Inc., and serves on the boards of vasopharm GmbH and D3O Holdings Ltd. Klaas received his M.Sc. degree in Applied Physics from Delft University of Technology and his M.B.A. from INSEAD.

Simon King

Simon King, PhD. has served as a member of the board of directors at SmartKem since January 2012 and is a Partner at Octopus Ventures, a London and New York based venture capital fund. At Octopus Ventures, Simon focuses on deeptech investing in early-stage companies. Simon received his M.A. and M.Sc. in Physics from Cambridge University and his Ph.D. in Physical Chemistry from Imperial College London.

Barbra Keck

Barbra Keck has served as a member of our board of directors since the Closing of the Exchange. Since February 2021, Barbra has served as the Chief Financial Officer of Deverra Therapeutics, Inc., a developer of cell therapies. From January 2009 until May 2020, she held positions of increasing responsibility at Delcath Systems, Inc., an interventional oncology company, starting as Controller and ultimately becoming a senior vice president in March 2015 and chief financial officer in February 2017. Barbra received an M.B.A. in Accountancy from Baruch College and a Bachelor of Music in Music Education from the University of Dayton.